Evotec and Immuneering bring iPSC, AI tech together in research tie-up

By Melissa Fassbender

- Last updated on GMT

Evotec and Immuneering bring iPSC, AI tech together in research tie-up

Related tags Evotec Immuneering Artificial intelligence AI iPSC

Evotec and Immuneering are combining iPSC and AI technologies through a research collaboration to discover novel small molecules for rare hereditary metabolic diseases.

To identify novel hits against targets of interest to Evotec​, Immuneering will apply an artificial intelligence​ (AI) based drug discovery platform to perform in silico​ high-throughput screens, said Greg Koytiger, SVP and head of AI at Immuneering. These can then be tested in Evotec's in vitro induced pluripotent stem cell (iPSC) platform​.

Dr. Werner Lanthaler, Evotec CEO, said the combination of iPSC and AI technologies creates an opportunity to discover novel metabolic ligands to accelerate drug discovery in rare metabolic diseases.

Lanthaler told us the goal is to develop novel drugs targeting disorders of lysosomes that drive different clinical presentations in many rare genetic metabolic and neurodegenerative diseases with a high unmet medical need.

Immuneering's proprietary computational drug discovery platform – Fluency – uses neural networks to predict binding affinity of vast chemical libraries to a target solely by its amino acid sequence, without the need for a crystal structure, explained Koytiger.

“Combining Evotec and Immuneering's platforms will enable us to very rapidly identify and validate novel small molecules that can become the basis of new preclinical drug programs for rare hereditary metabolic diseases,”​ Koytiger told us.

Financial details of the agreement were not disclosed.

Immuneering launched in February 2008, since which time it has partnered with several pharmaceutical companies to accelerate drug discovery and development.

The Cambridge, MA-based company applies proprietary computational biology methods and drug discovery platform to high-throughput molecular data. According to Immuneering, its platform can identify hits in days or weeks by applying AI and other algorithms.

Related news

Show more

Related products

show more

Saama accelerates data review processes

Saama accelerates data review processes

Content provided by Saama | 25-Mar-2024 | Infographic

In this new infographic, learn how Saama accelerates data review processes. Only Saama has AI/ML models trained for life sciences on over 300 million data...

More Data, More Insights, More Progress

More Data, More Insights, More Progress

Content provided by Saama | 04-Mar-2024 | Case Study

The sponsor’s clinical development team needed a flexible solution to quickly visualize patient and site data in a single location

Using Define-XML to build more efficient studies

Using Define-XML to build more efficient studies

Content provided by Formedix | 14-Nov-2023 | White Paper

It is commonly thought that Define-XML is simply a dataset descriptor: a way to document what datasets look like, including the names and labels of datasets...

Why should you use clinical trial technology?

Why should you use clinical trial technology?

Content provided by Formedix | 01-Nov-2023 | White Paper

New, innovative clinical trial technology is helping to revolutionize the research landscape. COVID-19 demonstrated that clinical trials can be run much...

Related suppliers

Follow us

Products

View more

Webinars